TCR2 Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- TCR2 Therapeutics's estimated annual revenue is currently $4.5M per year.
- TCR2 Therapeutics received $125.0M in venture funding in March 2018.
- TCR2 Therapeutics's estimated revenue per employee is $24,429
- TCR2 Therapeutics's total funding is $173.3M.
- TCR2 Therapeutics's current valuation is $153.3M. (January 2022)
- TCR2 Therapeutics has 184 Employees.
- TCR2 Therapeutics grew their employee count by 5% last year.
TCR2 Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is TCR2 Therapeutics?
TCR2 is an innovative immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer.keywords:Biotechnology,Healthcare
Number of Employees
Employee Growth %
TCR2 Therapeutics News
Zacks: Brokerages Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Announce Earnings of -$0.74 Per Share. Posted by admin on Apr 20th, 2022.
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from...
TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC-T Cell Therapies. Partnership enables TCR2 to evaluate multiple allogeneic candidates...
TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, ...
TCR² Therapeutics Inc. TCRR has been struggling lately, but the selling pressure may be coming to an end soon. That is because TCRR ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
TCR2 Therapeutics Funding
|2018-03-22||$125.0M||B||6 Dimensions Capital||Article|